Access, pricing and reimbursement; drug pricing issues; Medicare ESRD pharmaceutical access and reimbursement issues; ESRD benefit
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 9, 2026
- Income
- Not reported
- Expenses
- $520,000.00
- Registrant
- ARDELYX, INC.
- Client
- ARDELYX, INC.
- Filing UUID
- 57542dd7-8180-4f0a-939e-98a900bfcb2c
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.